Pregnancy and Multiple Sclerosis

ABSTRACT

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system affecting predominantly women of childbearing age; therefore, issues of conception, pregnancy, and delivery become of significant importance to patients and treating physicians. This article discusses the immunological and clinical effects of pregnancy on the course of MS, clinical outcomes of Pregnancy in Multiple Sclerosis (PRIMS) trials, the available data on safety and efficacy of immunomodulating MS treatments and symptomatic treatments for pregnant and lactating women, and specific issues of MS management at the time of pregnancy. The data related to estrogen-based MS therapies currently or previously in trials are reviewed. Pregnancy does not appear to be associated with adverse outcomes in MS patients. Some evidence suggests possible beneficial effects, although clear prospective data of sufficient length are limited. Long-term relapse rates and disability progression do not seem to be affected by pregnancy in MS patients. The use of immunosuppressive or immunomodulatory agents in pregnancy is not routinely advisable.

KEYWORDS

Multiple sclerosis - pregnancy

REFERENCES

• 1 Douglass L H, Jorgensen C L. Pregnancy and multiple sclerosis.  Am J Obstet Gynecol. 1948;  55 332-336
• 2 Confavreux C, Hutchinson M, Hours M, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis.  N Engl J Med. 1998;  339 285-291
• 3 Vukusic S, Hutchinson M, Hours M et al.. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.  Brain. 2004;  127 1353-1360
• 4 Rossouw J E, Anderson G L, Prentice R L et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial.  JAMA. 2002;  288 321-333
• 5 Thorogood M, Hannaford P C. The influence of oral contraceptives on the risk of multiple sclerosis.  Br J Obstet Gynaecol. 1998;  105 1296-1299
• 6 Alonso A, Jick S S, Olek M J, Ascherio A, Jick H, Hernán M A. Recent use of oral contraceptives and the risk of multiple sclerosis.  Arch Neurol. 2005;  62 1362-1365
• 7 Dwosh E, Guimond C, Sadovnick A D. Reproductive counselling for MS: a rationale.  Int MS J. 2003;  10 52-59
• 8 Zorzon M, Zivadinov R, Bosco A et al.. Sexual dysfunction in multiple sclerosis: a case-control study. Frequency and comparison of groups.  Mult Scler. 1999;  5 418-427
• 9 Hughes M D. Multiple sclerosis and pregnancy.  Neurol Clin. 2004;  22 757-769
• 10 Sadovnick A D, Baird P A, Ward R H. Multiple sclerosis: updated risks for relatives.  Am J Med Genet. 1988;  29 533-541
• 11 Hunt J S. Immunobiology of pregnancy.  Curr Opin Immunol. 1992;  4 591-596
• 12 Damek D M, Shuster E A. Pregnancy and multiple sclerosis.  Mayo Clin Proc. 1997;  72 977-989
• 13 Athanasas-Platsis S, Zhang B, Hillyard N C et al.. Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis.  J Neurol Sci. 2003;  214 27-36
• 14 Drew P D, Chavis J A. Female sex steroids: effects upon microglial cell activation.  J Neuroimmunol. 2000;  111 77-85
• 15 Gilmore W, Arias M, Stroud N, Stek A, McCarthy K A, Correale J. Preliminary studies of cytokine secretion patterns associated with pregnancy in MS patients.  J Neurol Sci. 2004;  224 69-76
• 16 Abramsky O, Brenner T, Mirzachi R, Soffer D. Alpha-fetoprotein suppresses experimental allergic encephalomyelitis.  J Neuroimmunol. 1982;  2 1-7
• 17 Altman D J, Schneider S L, Thompson D A, Cheng H L, Tomasi T B. A transforming growth factor beta 2 (TGF-beta-2)-like immunosuppressive factor in amniotic fluid and localization of TGF-beta 2 mRNA in the pregnant uterus.  J Exp Med. 1990;  172 1391-1401
• 18 Correale J, Gilmore W, McMillan M et al.. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T lymphocytes.  J Immunol. 1995;  154 2959-2968
• 19 Byrnes A A, McArthur J C, Karp C L. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin 10 production.  Ann Neurol. 2002;  51 165-174
• 20 López C, Comabellaa M, Tintoré M, Sastre-Garriga J. X Montalban X. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients.  Mult Scler. 2006;  12 421-427
• 21 Saraste M, Ryynänen J, Alanen J et al.. Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy.  J Neurol Neurosurg Psychiatry. 2006;  77 1195-1196
• 22 Weinshenker B G, Bass B, Rice G P et al.. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.  Brain. 1989;  112 133-146
• 23 Frith J A, Mcleod J G. Pregnancy and multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1988;  51 495-498
• 24 Birk K, Ford C, Smeltzer S et al.. The clinical course of multiple sclerosis during pregnancy and the puerperium.  Arch Neurol. 1990;  47 738-742
• 25 Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: The children of PRIMS.  Clin Neurol Neurosurg. 2006;  108 266-270
• 26 Kurtzke J F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS).  Neurology. 1983;  33 1444-1452
• 27 Salemi G, Callari G, Gammino M et al.. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study.  Acta Neurol Scand. 2004;  110 23-26
• 28 Runmarker B, Anderson O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis.  Brain. 1995;  118 253-261
• 29 Stenager E, Stenager E N, Jensen K. Effect of pregnancy on the prognosis for multiple sclerosis. A 5-year follow up investigation.  Acta Neurol Scand. 1994;  90 305-308
• 30 Mueller B A, Zhang J, Critchlow C W. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis.  Am J Obstet Gynecol. 2002;  186 446-452
• 31 Worthington J, Jones R, Crawford M et al.. Pregnancy and multiple sclerosis: a 3-year prospective study.  J Neurol. 1994;  241 228-233
• 32 Dahl J, Myhr K M, Daltveit A K, Hoff J M, Gilhus N E. Pregnancy, delivery, and birth outcome in women with multiple sclerosis.  Neurology. 2005;  65 1961-1963
• 33 de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis.  Mult Scler. 2004;  10 596-597
• 34 Janssen N M, Genta S G. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation.  Arch Intern Med. 2000;  160 610-619
• 35 Penn I, Makowski E, Droegemueller W, Halgrimson C G, Starzl T E. Parenthood in renal transplant recipients.  JAMA. 1971;  216 1755-1761
• 36 Kozlowski R D, Steinbrunner J V, McKenzie A H, Clough J D, Wilke W S, Segal A M. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease.  Am J Med. 1990;  88 589-592
• 37 Nguyen C, Duhl A J, Excallon C S, Blakemore K J. Multiple anomalies in a fetus exposed to a low-dose methotrexate in the first trimester of pregnancy.  Obstet Gynecol. 2002;  99 599-602
• 38 Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis.  Transplantation. 2001;  71 1051-1055
• 39 Walther E U, Hohlfeld R. Multiple sclerosis: side-effects of interferon beta therapy and their management.  Neurology. 1999;  53 1622-1627
• 40 Coyle P K, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate. In: Proceedings of the 55th Annual Meeting of the American Academy of Neurology.  Neurology. 2003;  60(suppl 1) A60
• 41 Boskovic R, Wide R, Wolpin J, Bauer D J, Koren G. The reproductive effects of beta interferon therapy in pregnancy. a longitudinal cohort.  Neurology. 2005;  65 807-811
• 42 Waubant E, Sadovnick A D. Interferon beta babies.  Neurology. 2005;  65 788-789
• 43 Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of child-birth-associated acute exacerbations in multiple sclerosis: a pilot study.  J Neurol. 1996;  243 25-28
• 44 Van Walderveen M AA, Tas M W, Barkhof F. Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis.  Neurology. 1994;  44 327-329
• 45 Voskuhl R R, Palaszynski K. Sex hormones and experimental autoimmune encephalomyelitis: implications for multiple sclerosis.  Neuroscientist. 2001;  7 258-270
• 46 Jansson L, Olsson T, Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice.  J Neuroimmunol. 1994;  53 203-207
• 47 Sicotte N L, Liva S M, Klutch R et al.. Treatment of multiple sclerosis with the pregnancy hormone estriol.  Ann Neurol. 2002;  52 421-428
• 48 Rizvi S A, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis.  Neurology. 2004;  63(suppl 6) S47-S54